Literature DB >> 28687250

Trends in the incidence of primary malignant brain tumors in Taiwan and correlation with comorbidities: A population-based study.

Ya-Jui Lin1, Hsiao-Yean Chiu2, Meng-Jiun Chiou3, Yin-Cheng Huang4, Kuo-Chen Wei4, Chang-Fu Kuo5, Jun-Te Hsu6, Pin-Yuan Chen7.   

Abstract

OBJECTIVE: Primary malignant brain tumors are relatively uncommon, and their incidence and survival rates have seldom been reported. PATIENTS AND METHODS: We identified all patients with malignant brain tumors in Taiwan between 1997 and 2012 using the National Health Insurance database. We estimated the stratified incidence of malignant brain tumors by age and sex. We estimated the median 1-, 2-, and 5-year survival, taking comorbidities into account. Trends for incidence and survival were analyzed using Joinpoint regression. The incidence in different geographic areas was also evaluated.
RESULTS: A total of 7746 men and 5846 women were identified. The incidence of malignant brain tumor was 3.34 (95% CI, 3.09-3.59) per 100,000 person-years in 1997 and 3.82 (95% CI, 3.56-4.08) per 100,000 person-years in 2012. The average annual percentage change (APC) of the standardized incidence over this period was 0.1 (95% CI, -1.9 to 2.2), suggesting a relatively stable incidence. However, the incidence significantly decreased between 1999 and 2012, with an APC of -1.8 [95% CI, -2.5 to -1.0]. One- and 5-year survival was 53.8% (50.0%-57.5%) and 27.5% (24.1%-30.9%) in 1997 and 67.6% (64.3%-70.7%) and 32.8% (29.6%-35.9%) in 2012. The average APC was 1.1 (95% CI, 0.7-1.5) for 1-year survival and 0.2 (95% CI, -1.0-1.4) for 5-year survival. The trend of improvement in the survival rate was seen for short-term but not long-term survival, especially in the group with more comorbidities.
CONCLUSIONS: A slightly decreased trend in incidence of primary malignant brain tumors was observed in Taiwanese general population since 1999. Over the past 15 years, the short-term survival of malignant brain tumors has improved, especially in adults.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  Comorbidity; Epidemiology; Incidence; Primary brain neoplasm; Survival

Mesh:

Year:  2017        PMID: 28687250     DOI: 10.1016/j.clineuro.2017.05.021

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

1.  CCL5 of glioma-associated microglia/macrophages regulates glioma migration and invasion via calcium-dependent matrix metalloproteinase 2.

Authors:  Caren Yu-Ju Wu; Chia-Hua Chen; Chun-Yen Lin; Li-Ying Feng; Yung-Chang Lin; Kuo-Chen Wei; Chiung-Yin Huang; Jia-You Fang; Pin-Yuan Chen
Journal:  Neuro Oncol       Date:  2020-02-20       Impact factor: 12.300

Review 2.  The Role of Myeloid Cells in GBM Immunosuppression.

Authors:  Ya-Jui Lin; Caren Yu-Ju Wu; Janet Yuling Wu; Michael Lim
Journal:  Front Immunol       Date:  2022-05-31       Impact factor: 8.786

3.  A Nationwide, Population-Based Epidemiology Study of Primary Central Nervous System Tumors in Korea, 2007-2016: A Comparison with United States Data.

Authors:  Ho Kang; Sang Woo Song; Johyun Ha; Young-Joo Won; Chul-Kee Park; Heon Yoo; Kyu-Won Jung
Journal:  Cancer Res Treat       Date:  2020-10-07       Impact factor: 4.679

4.  Epidemiologic Features, Survival, and Prognostic Factors Among Patients With Different Histologic Variants of Glioblastoma: Analysis of a Nationwide Database.

Authors:  Li-Tsun Shieh; Chung-Han Ho; How-Ran Guo; Chien-Cheng Huang; Yi-Chia Ho; Sheng-Yow Ho
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

5.  Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis.

Authors:  Qiong Zhan; Feng Miao; Ruofan Huang; Xinli Zhou; Mengxi Ge; Xiaohua Liang
Journal:  J Thorac Dis       Date:  2019-11       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.